Fuhong Hanlin has invested 70 million yuan in clinical trials of new drugs for gastric cancer and breast cancer
-
Last Update: 2019-02-13
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Fosun Pharmaceutical announced in the afternoon of February 12 that its holding subsidiaries Fuhong Hanlin and Hanlin pharmaceutical had recently received the approval from the State Drug Administration on the approval of hlx22 monoclonal antibody injection for clinical trials in the treatment of gastric cancer and breast cancer Fuhong Hanlin and Hanlin pharmaceutical plan to carry out phase I clinical trials of the new drug in the near future According to the announcement, up to now, there is no similar product with hlx22 McAb injection on the market worldwide As of January 2019, Fosun Pharmaceutical has invested about 70.67 million yuan (Unaudited) in research and development of the new drug at this stage The following is the original announcement:
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
